The advances in genetics and biochemistry that have taken place over the last 10 years led
to significant advances in experimental and clinical immunology. In turn, this has led to the …

Despite significant advances in oncological research, cancer nowadays remains one of the
main causes of mortality and morbidity worldwide. New treatment techniques, as a rule …

In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally
administered continuously at maximal tolerated dose until treatment failure. The majority of …

Clinical immunologists, among other problems, routinely face a question: what is the best
time and dose for a certain therapeutic agent to be administered to the patient in order to …

A mathematical model for the scheduling of angiogenic inhibitors in combination with a
chemotherapeutic agent is formulated. Conditions are given that allow tumor eradication …

The goal of cancer immunotherapy is to boost a patient's immune response to a tumour. Yet,
the design of an effective immunotherapy is complicated by various factors, including a …

Over the last few decades, there have been significant developments in theoretical,
experimental, and clinical approaches to understand the dynamics of cancer cells and their …

TGF-β is an immunoregulatory protein that contributes to inadequate antitumor immune
responses in cancer patients. Recent experimental data suggests that TGF-β inhibition …

A mathematical model describing the growth of tumor cells and the effect of impulsive
therapy is studied in this paper. The governing equations and parameters related to the …

Cancer therapies that harness the actions of the immune response, such as targeted
monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising …